Copyright
©The Author(s) 2020.
World J Gastroenterol. Aug 14, 2020; 26(30): 4489-4500
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4489
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4489
Variable | siTP group (n = 13) | seTP group (n = 17) | PVE-only group (n = 21) | P value |
FLR (%) (before hepatectomy) | 45.9 ± 4.2 | 43.3 ± 6.6 | 43.0 ± 4.7 | 0.262 |
Interval from TACE/PVE to hepatectomy | 16.2 ± 2.7 | 37.9 ± 6.5 | 35.4 ± 10.6 | < 0.001 |
KGR (%) | 21.1 ± 5.9 | 7.6 ± 2.9 | 6.8 ± 3.6 | < 0.001 |
Tumor size reduction, n (%) | 13 (100) | 13 (76) | 2 (10) | < 0.001 |
Complications, n (%) | 0.875 | |||
Abdominal pain | 6 (46) | 9 (53) | 3 (14) | |
Fever | 7 (54) | 8 (47) | 3 (14) | |
Nausea | 2 (15) | 4 (24) | 2 (10) | |
Acute pulmonary infarction | 0 | 1 (6) | 0 |
- Citation: Zhang CW, Dou CW, Zhang XL, Liu XQ, Huang DS, Hu ZM, Liu J. Simultaneous transcatheter arterial chemoembolization and portal vein embolization for patients with large hepatocellular carcinoma before major hepatectomy. World J Gastroenterol 2020; 26(30): 4489-4500
- URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4489.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4489